Attention: Late Cannabis Investors - Check This Out Now!
Experts say this technology could change everything for the retail cannabis market. So, if you were late last time, check this out now!
Click Here For The Full Story

THRG Insider Trading (BlackRock Throgmorton Trust)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £71,161.77
Insider Selling (Last 12 Months): GBX 0

BlackRock Throgmorton Trust Insider Trading History Chart

BlackRock Throgmorton Trust Share Price & Price History

GBX 910
▲ +7 (0.78%)
As of 06/22/2021 05:35 PM ET
Days: 30 | 90 | 365
One pot stock could skyrocket with looming interstate sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock

BlackRock Throgmorton Trust Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2021Louise NashInsiderBuy1,100GBX 914£10,054
6/11/2021Merryn S. WebbInsiderBuy1,768GBX 905£16,000.40
12/21/2020Angela LaneInsiderBuy2,122GBX 714£15,151.08
10/11/2020Angela LaneInsiderBuy17GBX 602£102.34
7/27/2020Angela LaneInsiderBuy875GBX 571£4,996.25
7/24/2020Angela LaneInsiderBuy4,361GBX 570£24,857.70
4/15/2020Christopher SamuelInsiderBuy180GBX 484£871.20
3/19/2020Christopher SamuelInsiderBuy25,000GBX 335£83,750
9/11/2019Louise NashInsiderBuy1,000GBX 570£5,700
4/12/2019Christopher SamuelInsiderBuy11,460GBX 521£59,706.60
3/11/2019Simon BeartInsiderBuy149GBX 499£743.51
2/11/2019Simon BeartInsiderBuy149GBX 497£740.53
1/10/2019Simon BeartInsiderBuy159GBX 466£740.94
12/21/2018Christopher SamuelInsiderBuy2,500GBX 443£11,075
12/11/2018Simon BeartInsiderBuy168GBX 443£744.24
11/12/2018Simon BeartInsiderBuy149GBX 497£740.53
10/10/2018Simon BeartInsiderBuy146GBX 509£743.14
9/11/2018Simon BeartInsiderBuy135GBX 550£742.50
8/10/2018Simon BeartInsiderBuy132GBX 563£743.16
7/11/2018Simon BeartInsiderBuy132GBX 564£744.48
See Full Table
BlackRock Throgmorton Trust plc is a closed-ended equity mutual fund launched by BlackRock Fund Managers Limited. It is managed by BlackRock Investment Management (UK) Limited. The fund invests in the public equity markets of the United Kingdom. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in stocks of small and mid-cap companies. It also invests through a portfolio of contracts for difference (CFD) and/or comparable equity derivatives. The fund employs fundamental analysis with a combination of top-down and bottom-up stock picking approaches, focusing on such factors as strong management and balance sheets, good technology, dependable niche business areas, and growth opportunity for shareholders to create its portfolio. It benchmarks the performance of its portfolio against the Numis Smaller Companies (excluding Investment Companies) Index. The fund was formerly known as The Throgmorton Trust Plc. BlackRock Throgmorton Trust plc was formed in December 1962 and is domiciled in the United Kingdom.
Read More on BlackRock Throgmorton Trust

Today's Range

Now: GBX 910

50 Day Range

MA: GBX 882.21

52 Week Range

Now: GBX 910


237,611 shs

Average Volume

226,972 shs

Market Capitalization

£851.20 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of BlackRock Throgmorton Trust?

BlackRock Throgmorton Trust's top insider shareholders include:
  1. Angela Lane (Insider)
  2. Christopher Samuel (Insider)
  3. Louise Nash (Insider)
  4. Merryn S Webb (Insider)
Revealed: A Real Solution for Depression?
Depression is the leading cause of disability worldwide. For nearly 100 million people… there's no known solution. That's right. Nearly one-third of the world's 322 million people suffering from depression have no existing treatment. But that's all about to change.
Here's how you could capitalize off this